Indeed, ICOS on T cells has been shown to favor the survival of effector-memory T cells (28, 29) promoting tumor immunity, and therefore, agonistic Abs targeting ICOS are under investigation in clinical trials for cancer immunotherapy, in combination with PD-1 blockade. Here, PDCD1 is linked to cancer.